



ROADMAP

P28 – ROADMAP: Real-world Data availability across Europe: What data are present, missing and heterogeneity of data collected

*28. Alzheimer Europe Meeting
29-31st October 2018 – Barcelona, Spain*

www.roadmap-alzheimer.org

P28.3 – Industry perspective on use and future development

Antje Hottgenroth Eli Lilly | 31st October 2018

“Successfully delivering therapies to the tens of millions in need will depend on building a sustainable approach that addresses the challenges and opportunities around treatment access at time of approval. In AD this will very much depend on the integration of real-world evidence (RWE) within health care systems to support evidence for approval as well as Health Technology Assessment and funding allocation.”



Project Leader and WorldWide Market Access Director NS at Novartis

Frédéric de Reydet de Vulpillieres

<https://roadmap-alzheimer.org/>

Understanding the challenges and opportunities around treatment access

- Epidemiology of the condition
- Etiology of the condition – disease trajectories
- Burden of the condition
 - Burden to effected people
 - Burden to the community/Health Care System
 - Burden to relatives
- Effect of interventions (treatments) on the disease trajectories
- Effect of interventions on the clinical and economic burden

WP3: Identification, mapping and integration of RWE Show more



Pieter-Jelle Visser -
Universiteit Maastricht
(UM)



Antje Hottgenroth - Eli Lilly
and Company Ltd (Eli Lilly)

WP3 will address the challenges related to finding, extracting, harmonising, integrating and analysing data from RWE sources relevant to AD.

<https://roadmap-alzheimer.org/>


Opportunities

- Access to large data sets gives a more comprehensive picture of patients as well as the opportunity to explore sub-populations and sub-groups
- Understanding of the behavior of treatments and outcomes in routine clinical practice
- Understanding the impact of treatments on the Health Care System: Health Care Resource Use and Costs

Challenges

- **Understanding the Real World Data Landscape** (existence, availability and suitability of data) for AD research
- Access to Real World Data depends on level of consent for usage and the ownership of the data and has to follow data privacy rules and regulations (e.g. EHR's often lacks consent for re-use)
- Every source of data provides a specific view on the condition and people with the condition – **there is no primary source of evidence**
- Physical/structural **segmentation of data sources and data types** makes it difficult to investigate the condition or the patients journey holistically
- Level of acceptance of Real World Data varies between stakeholders

AD-Stages vs.
AD-Outcomes



AD-Stages vs.
Data Sources

Data Sources vs.
AD-Outcomes

Challenges addressed

- Understanding the Real World Data Landscape (existence, availability and suitability of data) for AD research
- Access to Real World Data depends on level of consent for usage and the ownership of the data and has to follow data privacy rules and regulations (e.g. EHR's often lacks consent for re-use)
- Every source of data provides a specific view on the condition and people with the condition – there is no primary source of evidence
- Physical/structural segmentation of data sources and data types makes it difficult to investigate the condition or the patients journey holistically
- Level of acceptance of Real World Data varies between stakeholders

Data Cube Use Cases

- Selection of most appropriate data sources for research
- Negotiations with stakeholders on research feasibility
- Education (AD community, employees)

QUESTIONS?